OTCMKTS:AKSY

Aksys Competitors

$0.0005
0.00 (0.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.00
VolumeN/A
Average Volume28,225 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-6.76

Competitors

Aksys (OTCMKTS:AKSY) Vs. MDT, SONVY, VAR, MASI, GNGBY, and LIVN

Should you be buying AKSY stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Aksys, including Medtronic (MDT), Sonova (SONVY), Varian Medical Systems (VAR), Masimo (MASI), Getinge (GNGBY), and LivaNova (LIVN).

Aksys (OTCMKTS:AKSY) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares Aksys and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AksysN/AN/AN/A
Medtronic12.69%9.71%5.30%

Risk and Volatility

Aksys has a beta of -6.76, meaning that its stock price is 776% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Aksys and Medtronic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aksys0000N/A
Medtronic031812.91

Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 2.04%. Given Medtronic's higher probable upside, analysts clearly believe Medtronic is more favorable than Aksys.

Insider & Institutional Ownership

79.2% of Medtronic shares are held by institutional investors. 3.8% of Aksys shares are held by insiders. Comparatively, 0.5% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Aksys and Medtronic's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AksysN/AN/AN/AN/AN/A
Medtronic$28.91 billion5.68$4.79 billion$4.5926.53

Medtronic has higher revenue and earnings than Aksys.

Summary

Medtronic beats Aksys on 9 of the 10 factors compared between the two stocks.

Sonova (OTCMKTS:SONVY) and Aksys (OTCMKTS:AKSY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Sonova and Aksys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sonova06302.33
Aksys0000N/A

Institutional & Insider Ownership

1.1% of Sonova shares are owned by institutional investors. 3.8% of Aksys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Sonova has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Aksys has a beta of -6.76, suggesting that its stock price is 776% less volatile than the S&P 500.

Valuation and Earnings

This table compares Sonova and Aksys' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonova$2.96 billion6.13$489.96 million$1.4937.77
AksysN/AN/AN/AN/AN/A

Sonova has higher revenue and earnings than Aksys.

Profitability

This table compares Sonova and Aksys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SonovaN/AN/AN/A
AksysN/AN/AN/A

Summary

Sonova beats Aksys on 4 of the 5 factors compared between the two stocks.

Varian Medical Systems (NYSE:VAR) and Aksys (OTCMKTS:AKSY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Varian Medical Systems and Aksys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Varian Medical Systems35001.63
Aksys0000N/A

Varian Medical Systems currently has a consensus price target of $159.3571, indicating a potential downside of 10.03%. Given Varian Medical Systems' higher probable upside, research analysts plainly believe Varian Medical Systems is more favorable than Aksys.

Profitability

This table compares Varian Medical Systems and Aksys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Varian Medical Systems8.50%18.45%8.08%
AksysN/AN/AN/A

Risk & Volatility

Varian Medical Systems has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Aksys has a beta of -6.76, meaning that its share price is 776% less volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 0.8% of Varian Medical Systems shares are held by company insiders. Comparatively, 3.8% of Aksys shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Varian Medical Systems and Aksys' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.30
AksysN/AN/AN/AN/AN/A

Varian Medical Systems has higher revenue and earnings than Aksys.

Summary

Varian Medical Systems beats Aksys on 7 of the 8 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Aksys (OTCMKTS:AKSY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Risk and Volatility

Masimo has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Aksys has a beta of -6.76, meaning that its stock price is 776% less volatile than the S&P 500.

Institutional and Insider Ownership

81.6% of Masimo shares are held by institutional investors. 11.5% of Masimo shares are held by insiders. Comparatively, 3.8% of Aksys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Masimo and Aksys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Aksys0000N/A

Masimo currently has a consensus price target of $272.20, suggesting a potential upside of 15.97%. Given Masimo's higher probable upside, research analysts clearly believe Masimo is more favorable than Aksys.

Profitability

This table compares Masimo and Aksys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
AksysN/AN/AN/A

Valuation & Earnings

This table compares Masimo and Aksys' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million13.83$196.22 million$3.2272.89
AksysN/AN/AN/AN/AN/A

Masimo has higher revenue and earnings than Aksys.

Summary

Masimo beats Aksys on 9 of the 9 factors compared between the two stocks.

Aksys (OTCMKTS:AKSY) and Getinge (OTCMKTS:GNGBY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Insider & Institutional Ownership

0.0% of Getinge shares are owned by institutional investors. 3.8% of Aksys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Aksys and Getinge's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AksysN/AN/AN/A
Getinge10.51%17.30%7.90%

Valuation and Earnings

This table compares Aksys and Getinge's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AksysN/AN/AN/AN/AN/A
Getinge$2.81 billion2.70$129.29 millionN/AN/A

Getinge has higher revenue and earnings than Aksys.

Risk & Volatility

Aksys has a beta of -6.76, suggesting that its share price is 776% less volatile than the S&P 500. Comparatively, Getinge has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aksys and Getinge, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aksys0000N/A
Getinge11402.50

Summary

Getinge beats Aksys on 7 of the 8 factors compared between the two stocks.

Aksys (OTCMKTS:AKSY) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Aksys and LivaNova, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aksys0000N/A
LivaNova04202.33

LivaNova has a consensus price target of $67.50, suggesting a potential downside of 16.67%. Given LivaNova's higher possible upside, analysts plainly believe LivaNova is more favorable than Aksys.

Earnings & Valuation

This table compares Aksys and LivaNova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AksysN/AN/AN/AN/AN/A
LivaNova$1.08 billion3.64$-155,180,000.00$3.0826.30

Aksys has higher earnings, but lower revenue than LivaNova.

Profitability

This table compares Aksys and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AksysN/AN/AN/A
LivaNova-21.88%5.55%3.07%

Volatility and Risk

Aksys has a beta of -6.76, indicating that its share price is 776% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

89.1% of LivaNova shares are held by institutional investors. 3.8% of Aksys shares are held by company insiders. Comparatively, 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

LivaNova beats Aksys on 7 of the 9 factors compared between the two stocks.


Aksys Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$121.79flat$164.18 billion$28.91 billion46.48
Sonova logo
SONVY
Sonova
0.9$56.28flat$18.12 billion$2.96 billion37.77Analyst Upgrade
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.12flat$16.27 billion$3.17 billion60.45News Coverage
Masimo logo
MASI
Masimo
1.6$234.71flat$12.97 billion$937.84 million60.96Insider Selling
Getinge logo
GNGBY
Getinge
0.6$29.83flat$7.58 billion$2.81 billion24.65News Coverage
LivaNova logo
LIVN
LivaNova
1.5$81.00flat$3.94 billion$1.08 billion-18.84
CNMD
CONMED
1.6$134.43flat$3.89 billion$955.10 million-3,360.75
InMode logo
INMD
InMode
1.5$82.78flat$2.65 billion$156.36 million59.55
Outset Medical logo
OM
Outset Medical
0.9$55.61flat$2.38 billionN/A0.00
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$34.80flat$1.16 billion$27.37 million-47.67
NTUS
Natus Medical
1.1$26.09flat$883.77 million$495.52 million-47.44
AxoGen logo
AXGN
AxoGen
1.5$19.74flat$804.84 million$106.71 million-31.33
TransMedics Group logo
TMDX
TransMedics Group
1.6$28.61flat$783.06 million$23.60 million-20.44Insider Selling
SMLR
Semler Scientific
1.2$108.00flat$725.44 million$32.77 million76.06
ViewRay logo
VRAY
ViewRay
1.3$4.17flat$670.54 million$87.78 million-4.69
Stereotaxis logo
STXS
Stereotaxis
0.6$8.33flat$614.41 million$28.90 million-75.73High Trading Volume
News Coverage
Gap Down
Cutera logo
CUTR
Cutera
1.3$31.54flat$560.88 million$181.71 million-17.43
Zynex logo
ZYXI
Zynex
1.8$15.30flat$533.28 million$45.47 million46.36News Coverage
Edap Tms logo
EDAP
Edap Tms
1.3$8.81flat$256.74 million$50.23 million-146.83
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.65flat$201.11 million$3.38 million-4.53
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.35flat$138.29 millionN/A0.00
FONR
FONAR
1.1$18.01flat$118.04 million$85.69 million16.99
IRIDEX logo
IRIX
IRIDEX
0.9$7.22flat$112.06 million$43.45 million-13.13
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.35flat$97.76 million$10,000.00-1.28
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.12flat$89.29 millionN/A-1.47
electroCore logo
ECOR
electroCore
1.4$1.83flat$88.71 million$2.39 million-2.32
Electromed logo
ELMD
Electromed
1.8$10.05flat$86.78 million$32.47 million23.93News Coverage
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.28flat$39.93 million$1.50 million-0.99
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10flat$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.35flat$32.30 million$5.51 million-0.11
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.12flat$32.27 million$6.57 million-0.01
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.50flat$25.59 million$15.09 million0.00Gap Down
PEYE
Precision Optics
0.4$1.62flat$22.35 million$9.92 million-16.20Gap Up
Vaso logo
VASO
Vaso
0.9$0.12flat$21.30 million$75.75 million5.93News Coverage
Gap Up
STRR
Star Equity
0.1$3.24flat$15.95 million$114.18 million-1.03
Micron Solutions logo
MICR
Micron Solutions
0.1$3.48flat$11.70 million$17.50 million24.86
GTHP
Guided Therapeutics
0.3$0.81flat$10.41 million$40,000.00-3.35High Trading Volume
Gap Down
NIMU
Non-Invasive Monitoring Systems
0.5$0.03flat$2.69 millionN/A0.00
RSLSD
ReShape Lifesciences
0.5$5.37flat$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.02flat$1.20 millionN/A5.67
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$447,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$356,000.00N/A0.00
ULGX
Urologix
0.6$0.01flat$192,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00flat$177,000.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.34flat$0.00$9.40 million-5.67Gap Up
HRTT
Heart Tronics
0.0$0.15flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.